Related Experiment Video
Updated: Aug 6, 2026
07:08
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
Multiplex Panel Detects Glial and Inflammatory Biomarker Signatures in Sporadic and C9orf72-ALS
Karthik Baskar1,2,3, Christina Steffke1,2,3,4, Sarah Bernsen5,6
1Institute of Anatomy and Cell Biology, Ulm, Germany.
Neurology(R) Neuroimmunology & Neuroinflammation
|July 16, 2026
Summary
A novel assay identifies key biomarkers for amyotrophic lateral sclerosis (ALS) diagnosis and prognosis. This multiplexed approach uses minimal cerebrospinal fluid (CSF) to improve clinical feasibility for ALS research.
Area of Science:
- Neuroscience
- Biomarker Discovery
- Proteomics
Background:
- Cerebrospinal fluid (CSF) proteomics is crucial for identifying amyotrophic lateral sclerosis (ALS) biomarkers.
- Limited CSF sample availability hinders clinical application of current biomarker panels.
Purpose of the Study:
- To evaluate the nucleic acid-linked immuno-sandwich assay (NULISA) multiplex platform for ALS biomarker discovery.
- To validate known biomarkers and identify novel candidates using minimal CSF volumes.
Main Methods:
- A targeted panel of 131 biomarkers was measured using NULISA.
- Cohorts included patients with C9orf72-associated ALS, sporadic ALS (sALS), and healthy controls.
Main Results:
- Elevated levels of NEFH, NEFL, CHIT1, CHI3L1, CCL2, and CCL3 were observed in ALS patients compared to controls.
- Biomarkers correlated with disease progression and showed strong diagnostic performance.
- C9orf72-ALS patients displayed higher oxidative stress markers (PRDX6, ENO2) than sALS patients.
Conclusions:
- A multiplexed panel of diverse biomarkers complements neurofilament measurements for ALS diagnosis and prognosis.
- This approach enhances biomarker robustness and reduces CSF volume requirements, improving clinical feasibility.
